Company: LENZ
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001815776-25-000056
Chunk: 292

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-07-30
Form: 10-Q
Item: Part I, Item 1
Chunk 292
---
—— —— —— —— —— 1,597 — — 1,597 

4

Net loss—— —— —— —— —— — (10,254)— (10,254)Balance as of June 30, 2024—$— —$— —$— —$— 25,845,671$— $315,130 $(122,147)$(62)$192,921 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

(1)Retroactively recast for the reverse recapitalization as described in Note 3.

5

LENZ THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 

(in thousands)

(unaudited)

Six Months Ended June 30,20252024Cash flows from operating activitiesNet loss$(29,531)$(26,902)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization55 23 Loss on impairment of operating right-of-use assets and related property and equipment82 — Accretion of discounts on marketable securities(2,022)(1,234)Change in fair value of preferred stock warrants— 1,047 Share-based compensation expense5,400 2,544 Changes in operating assets and liabilities:Prepaid expenses and other current assets(1,196)(399)Accounts payable(1,628)(3,955)Accrued liabilities1,487 (9,479)Other assets(204)(1,377)Net cash used in operating activities(27,557)(39,732)Cash flows from investing activitiesPurchases of marketable securities(91,385)(111,257)Proceeds from maturities of marketable securities110,210 31,000 Purchases of property and equipment(350)(133)Net cash provided by (used in) investing activities18,475 (80,390)Cash flows from financing activitiesProceeds from issuance of common stock through at-the-market offerings, net of issuance costs26,067 — Proceeds from exercises of stock options240 3,843 Proceeds from issuance of common stock under employee stock purchase plan225 — Cash, cash equivalents, and restricted cash acquired in connection with the Merger— 117,824 Proceeds from issuance of common stock, net of